How fast will I lose weight on GLP-1s and is it sustainable?

Short answer

• Many people see the fastest weight loss in the first 3–6 months, then it slows.
• In clinical trials, modern GLP‑1/GIP drugs produced average body‑weight reductions roughly in these ranges after ~9–12+ months: semaglutide 2.4 mg (Wegovy) ≈ 10–15% of body weight; liraglutide 3.0 mg (Saxenda) ≈ 5–8%; tirzepatide (Zepbound/Mounjaro doses studied for weight loss) up to ~15–20% or more in some trials. Individual results vary a lot.
• Sustainability: benefits are usually maintained only while the medication and supportive behavior changes continue — stopping the drug often leads to weight regain unless lifestyle and other supports are in place.

What determines how fast/how much you’ll lose

• Drug and dose: higher effective doses (e.g., Wegovy 2.4 mg or tirzepatide 10–15 mg) produced larger mean losses in trials.
• Baseline weight: people with higher starting weight typically lose more pounds (and sometimes a larger percent).
• Adherence and escalation: getting to the target dose and staying on it matters.
• Lifestyle: combining medication with nutrition changes, physical activity, and behavioral support improves results.
• Biology and genetics: appetite set‑point, metabolism, sleep, stress, hormones, meds, and medical conditions affect speed and magnitude.
• Side effects: nausea/early satiety can cause big early losses but may limit dose escalation in some people.

Typical timeline to expect

• Weeks 0–12: appetite falls; many people lose a noticeable amount (often the steepest slope).
• Months 3–6: continued loss but often slower than month 1–3. Providers commonly reassess dose and co‑therapy in this window.
• 6–12+ months: some people reach a new lower steady weight; others continue modestly downward. Clinical trial endpoints are often at ~68–72 weeks because meaningful additional loss can occur out to ~1 year.

Is it sustainable?

• Short answer: partly — the biological signals that push body weight back up (increased hunger, reduced resting energy expenditure) persist. GLP‑1 and dual agents blunt those signals, so continuing the medication is often required to maintain much of the weight loss.
• Long‑term strategies that improve sustainability: ongoing medication when appropriate, structured nutrition plans, regular physical activity (resistance + aerobic), behavioral counseling or programs, treating sleep/mental‑health issues, and medical follow‑up.
• If you stop the drug, many people regain a sizable portion of lost weight within months to a couple years unless robust lifestyle/behavioral changes are established and maintained.

Safety, cost, and practical points

• Common side effects: nausea, constipation, diarrhea, abdominal pain; these often lessen over weeks as dose is increased slowly.
• Serious but rare risks: pancreatitis, gallbladder disease, and a rodent signal for medullary thyroid carcinoma for some GLP‑1s (discuss with your clinician if you have a personal/family history of certain thyroid cancers). Avoid in pregnancy/planning pregnancy.
• Cost/access: branded agents (Wegovy, Zepbound, Mounjaro/Ozempic for diabetes, Saxenda) can be expensive; insurance coverage varies. Expect to discuss cost and alternatives with your provider.

Brands to know (why they’re often chosen)

• Wegovy (semaglutide 2.4 mg): FDA‑approved specifically for chronic weight management; strong clinical trial evidence for ~10–15% average loss at ~1 year.
• Zepbound (tirzepatide) and Mounjaro (tirzepatide — Mounjaro is approved for type 2 diabetes; tirzepatide was studied for weight loss and Zepbound is the weight‑management brand): dual GIP/GLP‑1 action; trials showed larger average weight losses than earlier GLP‑1s for many people.
• Saxenda (liraglutide 3.0 mg): older GLP‑1 approved for weight management; produces modest but meaningful weight loss for some people.

Next steps I recommend

1. Talk with a clinician experienced in weight management (look for an obesity medicine specialist or a provider certified by the American Board of Obesity Medicine) to review whether a GLP‑1/GIP drug is appropriate for you.
2. Discuss goals, risks, insurance/cost, dose escalation schedule, and monitoring plan.
3. Combine medication with a structured plan for nutrition, activity, sleep, and behavioral support to maximize results and improve sustainability.

If you want, tell me your starting weight, medical history (diabetes, pregnancy, eating disorders, pancreatitis, thyroid cancer family history), and whether you have preferred brands or budget limits — I can give a more personalized expectation and next‑step plan.